Amneal Pharmaceuticals (NASDAQ:AMRX) Downgraded by Zacks Research to Strong Sell

Zacks Research lowered shares of Amneal Pharmaceuticals (NASDAQ:AMRX) from a hold rating to a strong sell rating in a report released on Tuesday,Zacks reports.

A number of other analysts have also weighed in on the company. Barclays increased their target price on Amneal Pharmaceuticals from $16.00 to $20.00 and gave the stock an “overweight” rating in a research note on Thursday, September 17th. The Goldman Sachs Group restated a “buy” rating and issued a $21.00 price target on shares of Amneal Pharmaceuticals in a report on Friday, July 31st. Leerink Partners assumed coverage on shares of Amneal Pharmaceuticals in a research note on Wednesday, September 9th. They issued an “outperform” rating and a $23.00 price target on the stock. Weiss Ratings upgraded shares of Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 26th. Finally, Oppenheimer assumed coverage on shares of Amneal Pharmaceuticals in a research report on Wednesday, September 23rd. They issued an “outperform” rating and a $27.00 price objective for the company. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.00.

Amneal Pharmaceuticals Stock Down 3.2%

Shares of NASDAQ:AMRX opened at $19.65 on Tuesday. Amneal Pharmaceuticals has a 1 year low of $9.56 and a 1 year high of $21.17. The business has a 50 day simple moving average of $18.40 and a two-hundred day simple moving average of $15.84. The firm has a market capitalization of $6.28 billion, a PE ratio of 40.10, a price-to-earnings-growth ratio of 2.38 and a beta of 1.22. The company has a debt-to-equity ratio of 77.65, a current ratio of 2.20 and a quick ratio of 1.44.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its earnings results on Thursday, July 30th. The company reported $0.30 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $0.06. Amneal Pharmaceuticals had a negative return on equity of 584.46% and a net margin of 5.05%.The firm had revenue of $796.20 million for the quarter. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. On average, equities analysts predict that Amneal Pharmaceuticals will post 0.95 EPS for the current year.

Insider Activity

In other Amneal Pharmaceuticals news, EVP Jason B. Daly sold 210,000 shares of the stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $17.40, for a total transaction of $3,654,000.00. Following the transaction, the executive vice president directly owned 35,171 shares in the company, valued at $611,975.40. This represents a 85.65% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Nikita Shah sold 146,403 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $17.51, for a total transaction of $2,563,516.53. Following the transaction, the executive vice president directly owned 253,390 shares in the company, valued at $4,436,858.90. This trade represents a 36.62% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 413,016 shares of company stock worth $7,216,567. Company insiders own 17.30% of the company’s stock.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Several large investors have recently modified their holdings of the business. Arizona State Retirement System boosted its position in Amneal Pharmaceuticals by 1.9% in the second quarter. Arizona State Retirement System now owns 44,011 shares of the company’s stock valued at $762,000 after buying an additional 837 shares during the last quarter. Hsbc Holdings PLC raised its position in Amneal Pharmaceuticals by 1.6% during the 4th quarter. Hsbc Holdings PLC now owns 101,945 shares of the company’s stock worth $1,297,000 after buying an additional 1,569 shares during the last quarter. Public Employees Retirement System of Ohio purchased a new position in Amneal Pharmaceuticals during the 2nd quarter worth approximately $29,000. Handelsbanken Fonder AB lifted its stake in Amneal Pharmaceuticals by 3.0% during the 2nd quarter. Handelsbanken Fonder AB now owns 76,400 shares of the company’s stock valued at $1,322,000 after acquiring an additional 2,200 shares during the period. Finally, Royal Bank of Canada lifted its stake in Amneal Pharmaceuticals by 33.7% during the 1st quarter. Royal Bank of Canada now owns 12,646 shares of the company’s stock valued at $157,000 after acquiring an additional 3,191 shares during the period. Institutional investors own 31.82% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a global pharmaceutical company that develops, manufactures and markets a broad portfolio of generic and specialty medicines. The company focuses on complex and difficult-to-manufacture products, including injectables, biosimilars, ophthalmic medicines, respiratory treatments, oncology products, transdermal formulations and other dosage forms.

Amneal also operates a specialty pharmaceutical business focused on branded products in areas such as central nervous system disorders, endocrinology and other therapeutic categories.